Novartis Reports Positive Result For Phase-II Trial Of Afinitor, Sandostatin LAR

Published: 25-Jun-2009

Showed patients, who received Afinitor in combination with Sandostatin LAR, remained progression-free for 16.7 months

Novartis' new study demonstrated that treatment with Afinitor (everolimus) tablets, in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy, may have the potential to control tumor growth in patients with advanced pancreatic neuroendocrine tumors (NET).

RADIANT-1 is a phase II study of 160 patients, with pancreatic NET resistant to treatment with cytotoxic chemotherapy. The final analysis showed that patients who received Afinitor in combination with Sandostatin LAR, remained progression-free for a median of 16.7 months, nearly four additional months since the first analysis was reported.

In addition, 84% of patients receiving combination therapy experienced a decrease in tumor size. Patients who took Afinitor monotherapy remained progression-free for 9.7 months, and nearly 60% of patients experienced a decrease in tumor size.

Alessandro Riva, Executive Vice President and Global Head, Novartis Oncology Development, said: We hope that the biomarkers being studied in this trial will provide valuable insights into which patients are most likely to benefit from Afinitor, furthering our aim of providing the right drug for the right patients.

Tell your friend about this article